A case of leptomeningeal metastasis from adenocarcinoma of the lung improved by treatment with Gefitinib.
- Author:
Sung Ken YU
1
;
Won Jong PARK
;
Chan Soh PARK
;
Hyun Jung CHIN
;
Kyeong Cheol SHIN
;
Jin Hong CHUNG
;
Kwan Ho LEE
Author Information
1. Department of Internal Medicine, Yeungnam University College of Medicine, Daegu, Korea. jhchn@med.yu.ac.kr
- Publication Type:Case Report
- Keywords:
Leptomeningeal metastasis;
Non-small cell lung cancer;
Gefitinib
- MeSH:
Adenocarcinoma;
Blood-Brain Barrier;
Brain;
Carcinoma, Non-Small-Cell Lung;
Humans;
Lung;
Neoplasm Metastasis;
Quinazolines
- From:Korean Journal of Medicine
2008;74(2):198-202
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Leptomeningeal metastasis occurs in approximately 1% of patients with non-small cell lung cancer and this is an extremely serious complication. Without treatment, the median survival of patients is 4~6 weeks. The treatment options currently available are limited and achieve only modest results. Gefitinib was recently approved for the treatment of advanced/refractory non-small cell lung cancer. In addition, there have been case reports showing activity of gefitinib against brain metastasis in non-small cell lung cancer patients. However, there is limited data on the ability of gefitinib to cross the blood-brain barrier. We report the case of a patient with leptomeningeal metastasis from adenocarcinoma of the lung that had a dramatic response to gefitinib treatment.
